EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Assessment of body mass-related covariates for rifampicin pharmacokinetics in healthy Caucasian volunteers

Muhammad Bilal, Sami Ullah, Ulrich Jaehde, Christina Trueck, Dario Zaremba, Bertil Wachall, Manfred Wargenau, Bernhard Scheidel, Martin H J Wiesen, Malaz Gazzaz, Chunli Chen, Sören Büsker und 3 weitere

European Journal of Clinical Pharmacology · 2024-09 · 80 (9) · 1271-1283

DOI: 10.1007/s00228-024-03697-3 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 09.05.2024. Verfasst von Muhammad Bilal und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department I of Pharmacology, Center for Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. …. Hauptthemen laut MEDLINE: Rifampin, White People, Models, Biological, Healthy Volunteers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 2022 ESI International High Impact Research Article Cooperation Program, the National Natural Science Foundation of Heilongjiang Province, International Postdoctoral Exchange Fellowship Program from the Office of China Postdoctoral Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Currently, body weight-based dosing of rifampicin is recommended. But lately, fat-free mass (FFM) was reported to be superior to body weight (BW). The present evaluation aimed to assess the influence of body mass-related covariates on rifampicin’s pharmacokinetics (PK) parameters in more detail using non-linear mixed effects modeling (NLMEM).

Methods

Twenty-four healthy Caucasian volunteers were enrolled in a bioequivalence study, each receiving a test and a reference tablet of 600 mg of rifampicin separated by a wash-out period of at least 9 days. Monolix version 2023R1 was used for NLMEM. Monte Carlo simulations (MCS) were performed to visualize the relationship of body size descriptors to the exposure to rifampicin.

Results

A one-compartment model with nonlinear (Michaelis–Menten) elimination and zero-order absorption kinetics with a lag time best described the data. The covariate model including fat-free mass (FFM) on volume of distribution (V/F) and on maximum elimination rate (Vmax/F) lowered the objective function value (OFV) by 56.4. The second-best covariate model of sex on V/F and Vmax/F and BW on V/F reduced the OFV by 51.2. The decrease in unexplained inter-individual variability on Vmax/F in both covariate models was similar. For a given dose, MCS showed lower exposure to rifampicin with higher FFM and accordingly in males compared to females with the same BW and body height.

Conclusion

Our results indicate that beyond BW, body composition as reflected by FFM could also be relevant for optimized dosing of rifampicin. This assumption needs to be studied further in patients treated with rifampicin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinWhite PeopleModels, BiologicalHealthy VolunteersHumansMaleFemaleAdultYoung AdultTherapeutic EquivalencyMonte Carlo MethodAntibiotics, AntitubercularBody WeightCross-Over StudiesNonlinear Dynamics

Stichwörter der Autor:innen

Body weightCovariate modelingFat-free massPopulation pharmacokineticsRifampicin

Substanzen

RifampinAntibiotics, Antitubercular

Autor:innen und Institutionen

  • Department I of Pharmacology, Center for Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. muhammad.bilal@uk-koeln.de.
  • Department of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, Bonn, Germany. muhammad.bilal@uk-koeln.de.
  • Department I of Pharmacology, Center for Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Department of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, Bonn, Germany.
  • InfectoPharm Arzneimittel Und Consilium GmbH, 64646, Heppenheim, Germany.
  • M.A.R.C.O. GmbH & Co. KG, Dusseldorf, Germany.

Förderung

  • 2022 ESI International High Impact Research Article Cooperation Program
  • the National Natural Science Foundation of Heilongjiang Province
  • International Postdoctoral Exchange Fellowship Program from the Office of China Postdoctoral Council
  • German Academic Exchange Service
  • Government of Saudi Arabia
  • Universitätsklinikum Köln

Zitieren

APA

Bilal, M., Ullah, S., Jaehde, U., Trueck, C., Zaremba, D., Wachall, B., Wargenau, M., Scheidel, B., Wiesen, M. H. J., Gazzaz, M., Chen, C., Büsker, S., Fuhr, U., Taubert, M., & Dokos, C. (2024). Assessment of body mass-related covariates for rifampicin pharmacokinetics in healthy Caucasian volunteers. European Journal of Clinical Pharmacology, 80(9), 1271-1283. https://doi.org/10.1007/s00228-024-03697-3

Vancouver

Bilal M, Ullah S, Jaehde U, Trueck C, Zaremba D, Wachall B, et al. Assessment of body mass-related covariates for rifampicin pharmacokinetics in healthy Caucasian volunteers. European Journal of Clinical Pharmacology. 2024;80(9):1271-1283. doi:10.1007/s00228-024-03697-3

BibTeX
@article{Bilal2024,
  author = {Bilal, Muhammad and Ullah, Sami and Jaehde, Ulrich and Trueck, Christina and Zaremba, Dario and Wachall, Bertil and Wargenau, Manfred and Scheidel, Bernhard and Wiesen, Martin H J and Gazzaz, Malaz and Chen, Chunli and Büsker, Sören and Fuhr, Uwe and Taubert, Max and Dokos, Charalambos},
  title = {Assessment of body mass-related covariates for rifampicin pharmacokinetics in healthy Caucasian volunteers},
  journal = {European Journal of Clinical Pharmacology},
  year = {2024},
  volume = {80},
  number = {9},
  pages = {1271--1283},
  doi = {10.1007/s00228-024-03697-3}
}
Kostenlos starten →